Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (50 quarters reported)
$226M in Q2 2013 → $44.5M now. Hover for any quarter.
As reported for the quarter ended September 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Entrada Therapeutics, Inc. | 57.1% | Unchanged | 4,381,062 | $25.4M |
| Dyne Therapeutics, Inc. | 19.4% | Unchanged | 682,376 | $8.63M |
| Werewolf Therapeutics, Inc. | 19.1% | Unchanged | 4,309,860 | $8.49M |
| Repare Therapeutics, Inc. | 4.4% | Unchanged | 1,121,318 | $1.97M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Adaptimmune Therapeutics PLC | Exited | −4,809,677 | −$1.15M | — |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Iteos Therapeutics, Inc. | Exited | −2,738,785 | −$16.4M | — |
| Adaptimmune Therapeutics PLC | Trimmed | −526,038 | −$126K | 2.7% |
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Repare Therapeutics, Inc. | Trimmed | −562,389 | −$555K | 1.6% |
| Adaptimmune Therapeutics PLC | Trimmed | −219,746 | −$43.3K | 1.5% |
| Werewolf Therapeutics, Inc. | Added | +25,688 | +$25K | 6.0% |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Entrada Therapeutics, Inc. | Trimmed | −44,722 | −$773K | 60.9% |
| Repare Therapeutics, Inc. | Trimmed | −558,929 | −$732K | 1.8% |
quarter ended September 30, 2024 · filed November 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Dyne Therapeutics, Inc. | Trimmed | −879,120 | −$31.6M | 16.9% |
quarter ended June 30, 2024 · filed August 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Dyne Therapeutics, Inc. | Trimmed | −1,889,807 | −$66.7M | 30.3% |
quarter ended March 31, 2024 · filed May 15, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Dyne Therapeutics, Inc. | Trimmed | −1,500,000 | −$42.6M | 40.0% |
| Harpoon Therapeutics, Inc. | Exited | −313,136 | −$3.56M | — |
quarter ended December 31, 2023 · filed February 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Harpoon Therapeutics, Inc. | New | +313,136 | +$3.56M | 1.7% |
| Harpoon Therapeutics, Inc. | Exited | −313,136 | −$1.26M | — |
| Adaptimmune Therapeutics PLC | Trimmed | −731,640 | −$580K | 2.2% |
Loading...
